Cargando…
Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond
SIMPLE SUMMARY: In the latest WHO classification, solitary fibrous tumors (SFTs) are now subdivided into benign SFT (intermediate category (locally aggressive)), SFT NOS (intermediate category (rarely metastasizing)), and malignant SFT. Thanks to recent progress in molecular characterization, the id...
Autores principales: | de Bernardi, Axel, Dufresne, Armelle, Mishellany, Florence, Blay, Jean-Yves, Ray-Coquard, Isabelle, Brahmi, Mehdi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870479/ https://www.ncbi.nlm.nih.gov/pubmed/35205812 http://dx.doi.org/10.3390/cancers14041064 |
Ejemplares similares
-
Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience
por: Levard, Alice, et al.
Publicado: (2013) -
Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
por: Fazel, Mina, et al.
Publicado: (2023) -
KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome
por: Brahmi, Mehdi, et al.
Publicado: (2015) -
Refining Prognosis in Localized Gastrointestinal Stromal Tumor: Clinical Significance of Phosphatase and Tensin Homolog Low Expression and Gene Loss
por: Feng, Xiaolan, et al.
Publicado: (2022) -
Expanding the molecular spectrum of tenosynovial giant cell tumors
por: Gauduchon, Thibault, et al.
Publicado: (2022)